SMS Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 31, 2025, titled "Press Release on Financial Results".
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals reported strong FY25 results, with PAT growing 39% YoY to ₹69.14 crore on revenue of ₹782.75 crore (up 10% YoY). EBITDA margin expanded by 132 basis points to 18%, driven by backward integration and improved product mix. Q4FY25 saw a strong 43% QoQ revenue recovery to ₹248.20 crore, with PAT of ₹20.31 crore (up 18% YoY). The anti-inflammatory segment (including ibuprofen) grew 22% YoY, and anti-epileptics surged 106% YoY. The Board recommended a final dividend of ₹0.40 (40%) per share, and the company outlined a ₹250 crore capex plan over the next 18 months to expand API capacity and CMO business.
Strong earnings beat, margin expansion, and forward guidance of 20% revenue growth with 20% EBITDA margin in FY26 signal continued momentum, likely positive for the stock. The dividend announcement and ₹250 crore growth capex reinforce management's confidence in future prospects.